KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables: 2009-2024

Historic Receivables for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $660.5 million.

  • Biomarin Pharmaceutical's Receivables rose 1.64% to $790.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 11.18%. This contributed to the annual value of $660.5 million for FY2024, which is 4.23% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Receivables stood at $660.5 million, which was up 4.23% from $633.7 million recorded in FY2023.
  • Biomarin Pharmaceutical's Receivables' 5-year high stood at $660.5 million during FY2024, with a 5-year trough of $373.4 million in FY2021.
  • For the 3-year period, Biomarin Pharmaceutical's Receivables averaged around $585.2 million, with its median value being $633.7 million (2023).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Receivables declined by 16.72% in 2021, and later skyrocketed by 37.37% in 2023.
  • Biomarin Pharmaceutical's Receivables (Yearly) stood at $448.4 million in 2020, then declined by 16.72% to $373.4 million in 2021, then climbed by 23.55% to $461.3 million in 2022, then soared by 37.37% to $633.7 million in 2023, then increased by 4.23% to $660.5 million in 2024.